Odefsey - Another NNRTI Combination for HIV

Date:  May 9, 2016 Issue #:  1494 Summary:  The FDA has approved Odefsey (Gilead), a once-daily, fixed-dose combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection in patients with HIV-1 RNA (viral load) ≤100,000 copies/mL or to replace a stable antiretroviral regimen in patients who have been virologically suppressed (viral load <50 copies/mL) for at least six months with no history of treatment failure.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Atripla cobicistat Complera darunavir Descovy Efavirenz elvitegravir Emtricitabine Genvoya hepatitis b NNRTIs Odefsey Protease inhibitors rilpivirine Tenofovir tenofovir alafenamide Source Type: research